Merck (MRK) reported Q2 FY 2018 earnings of $1.06 per share (versus $1.01 in Q2 FY 2017), beating analysts' consensus estimate of $1.03.

The company's quarterly revenues amounted to $10.465 bln (+5.4% y/y), beating analysts' consensus estimate of $10.280 bln.

The company also issued in-line guidance for FY 2018, projecting EPS of $4.22-4.30 (versus its prior guidance of $4.16-4.28 and analysts' consensus estimate of $4.24) and revenues of $42-42.8 bln (versus its prior guidance of $41.8-43 bln and analysts' consensus estimate of $42.12 bln).

MRK rose to $64.98 (+1.52%) in pre-market trading.